As shown in our previous study of GBM (Arif et al., 2017; Shteinfer‐Kuzmine et al., 2017), the R‐Tf‐D‐LP4 peptide eliminated CSCs in tumors derived from glioblastoma, lung, and breast cancers (Fig. 9). This evidence concerns the gene TF and glioblastoma.